1-3 of 3
Danan Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor

Kai Wang, Qin Zhang, Danan Li, Keith Ching, Cathy Zhang, Xianxian Zheng, Mark Ozeck, Stephanie Shi, Xiaorong Li, Hui Wang, Paul Rejto, James Christensen, Peter Olson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (6): 1487–1496.
https://doi.org/10.1158/1078-0432.CCR-14-1348
Published: 12 March 2015
View article titled, PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor
Open the PDF for PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor in another window
Includes: Supplementary data
Journal Articles

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Takeshi Shimamura, Samanthi A. Perera, Kevin P. Foley, Jim Sang, Scott J. Rodig, Takayo Inoue, Liang Chen, Danan Li, Julian Carretero, Yu-Chen Li, Papiya Sinha, Christopher D. Carey, Christa L. Borgman, John-Paul Jimenez, Matthew Meyerson, Weiwen Ying, James Barsoum, Kwok-Kin Wong, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (18): 4973–4985.
https://doi.org/10.1158/1078-0432.CCR-11-2967
Published: 16 September 2012
View article titled, Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <em>In Vitro</em> and <em>In Vivo</em> Models of Non–Small Cell Lung Cancer
Open the PDF for Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <em>In Vitro</em> and <em>In Vivo</em> Models of Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

Geoffrey D. Girnun, Liang Chen, Jessica Silvaggi, Ronny Drapkin, Lucian R. Chirieac, Robert F. Padera, Rabi Upadhyay, Scott B. Vafai, Ralph Weissleder, Umar Mahmood, Elnaz Naseri, Stephanie Buckley, Danan Li, Jeremy Force, Kate McNamara, George Demetri, Bruce M. Spiegelman, Kwok-Kin Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6478–6486.
https://doi.org/10.1158/1078-0432.CCR-08-1128
Published: 16 October 2008
View article titled, Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin
Open the PDF for Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin in another window